Innovative & workable solutions for your complex legal problems

The Bombay High Court criticised the Maharashtra FDA for suspending the food business licence of a four star hotel over the discovery of two insects, observing that the action appeared disproportionate in light of an otherwise satisfactory inspection report. The Court emphasised that regulatory enforcement must be fair, consistent and proportionate, and set aside the suspension order.

A manufacturer has reportedly challenged the Food Safety and Standards Authority of India before the Bombay High Court against its order restricting sales of a rum product over alleged labelling violations. The company maintains its labels comply with regulations and industry practice, while describing the dispute as an industry-wide regulatory issue.

The Ministry of Road Transport and Highways has proposed additions of two-wheeled road ambulances Central Motor Vehicles Rules, 1989 to provide emergency response in rural, remote and hilly terrain. The draft introduces uniform safety, construction, registration, and fitness standards to strengthen last-mile emergency medical response. The draft has been opened for a 30-day public consultation period, after which the rules will be finalized.

A Delhi court has ordered that charges be framed in a case involving the alleged illegal possession and seizure of codeine-based cough syrup under narcotics law, finding sufficient grounds to proceed to trial. The order clears the way for formal prosecution and further judicial proceedings in the matter.

India's central government is reportedly considering a comprehensive national regulatory and patient safety framework for dental implants, implant biomaterials, artificial teeth and related implant systems. The proposed framework aims to strengthen regulatory oversight, improve quality and safety standards, and ensure greater accountability across the dental implant ecosystem amid rising adoption in India.

The Central Drugs Standard Control Organisation will launch the first phase of the Digital Drug Regulatory System within eighteen months. The integrated online platform will simplify regulatory approvals, improve transparency, strengthen medicine traceability, use artificial intelligence for faster processing, and help pharmaceutical companies meet compliance requirements through a single digital window.

A parliamentary panel has recommended that the Department of Pharmaceuticals regulate prices of trade generic medicines distributed through separate marketing channels, citing concerns over excessive markups and affordability in rural and remote markets. If implemented, the proposal could improve access to reasonably priced medicines through greater pricing oversight.

The Maharashtra Food and Drug Administration (FDA) has identified several medicines allegedly being sold at excessive prices and plans to refer these cases to the National Pharmaceutical Pricing Authority (NPPA) for regulatory action. The FDA has also indicated that it will intensify surveillance of drug pricing and investigate instances of unreasonable mark-ups to strengthen compliance with pricing regulations.

India's major manufacturer of eye drops has reportedly voluntarily recalled a batch of eye drops in India after contamination concerns were identified during quality checks. The company initiated the recall as a precautionary measure, informed the concerned authorities, and advised distributors to withdraw the affected batch while reiterating its commitment to patient safety and product quality.

FSSAI has reportedly intensified enforcement against three food businesses and has ordered recall of raisins for excessive pesticide residues; suspended Pharmaceuticals’ manufacturing licence over critical compliance failures and prohibition order for marketing as a food supplement with misleading claims of folic acid syrup and non-compliance of FSSAI Regulations, 2016. These actions were taken to protect consumers and warned of strict consequences for violations.

The Food Safety and Standards Authority of India (FSSAI) has issued notices to six beverage manufacturers over the use of the term "energy drink" and related misbranding and misleading claims. The regulator observed that there is currently no notified standard for products classified as "energy drinks" under the Food Safety and Standards framework, and objected to promotional claims suggesting functional or therapeutic benefits, such as boosting energy or enhancing focus. The action reinforces FSSAI's ongoing efforts to ensure compliance with food labelling and advertising regulations and to prevent misleading claims that may deceive consumers. 

The Department of Pharmaceuticals has clarified the framework governing overcharging liability under the Drugs (Prices Control) Order, 2013. Manufacturers demonstrating compliance with prescribed price communication requirements will have their liability restricted to the quantity of stock actually overcharged by distributors or retailers, providing greater regulatory certainty.

The Department of Pharmaceuticals has amended the Drugs (Prices Control) Order, 2013 to introduce Form IA for intimating new drug launches. The amendment simplifies the launch process for existing manufacturers by replacing the requirement for fresh retail price approval with a post-launch intimation within one month.

India's Central Drugs Standard Control Organisation (CDSCO) is undertaking a nationwide reconciliation exercise to identify and authenticate missing drug approvals from 1945, including legacy products approved by State Licensing Authorities (SLA) before 1988. Manufacturers will be required to submit historical approval records to help create a comprehensive national repository, address gaps in the CDSCO approval database, improve regulatory oversight, and verify that older formulations comply with current safety and efficacy standards. 

The Department of Pharmaceuticals has amended the Drugs (Prices Control) Order, 2013 to permit separate ceiling or retail prices for therapeutically justified variants of the same drug. The amendment recognizes differences in packaging, pack size, dosage compliance, and dosage form while determining regulated prices.

The Department of Pharmaceuticals has strengthened record-keeping requirements under the Drugs (Prices Control) Order, 2013. Manufacturers must maintain records relating to APIs, bulk drugs, formulations, and other prescribed information for at least seven financial years, with records retained until the conclusion of any pending proceedings, if any.

The Ministry of Health and Family Welfare has notified amendments to the Drugs Rules, 1945, expanding their scope to expressly cover cell or stem cell-derived products, gene therapeutic products, and xenografts alongside recombinant DNA (r-DNA) derived drugs. The amendments take effect from the date of publication in the Official Gazette. 

India's Delhi Anti-Corruption Branch (ACB) reports have alleged ₹600 crore procurement scam involving the directorate general of health services (DGHS) and the central procurement agency (CPA). The scam includes claims of changing tender rules, using fake companies, and raising prices for medical supplies. Items like X-ray machines, bedsheets, and ORS sachets were bought at much higher prices than usual. Three officials have been arrested, and the investigation continues to uncover more information.